Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens-Reference-Cited by-同舟云学术

Tacrolimus initial steady state level in post-transplant cyclophosphamide-based GvHD prophylaxis regimens

Published:2021-11-20 Issue:2 Volume:57 Page:232-242
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Yao Janny M.,Yang Dongyun,Clark Mary C.,Otoukesh Salman,Cao Thai,Ali Haris^ORCID,Arslan Shukaib^ORCID,Aldoss Ibrahim,Artz Andrew^ORCID,Amanam Idoroenyi,Salhotra Amandeep,Pullarkat Vinod,Sandhu Karamjeet^ORCID,Stein Anthony,Marcucci Guido,Forman Stephen J.,Nakamura Ryotaro^ORCID,Al Malki Monzr M.^ORCID

Funder

U.S. Department of Health & Human Services | National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01528-y.pdf

Reference29 articles.

1. Ciurea SO, Zhang MJ, Bacigalupo AA, Bashey A, Appelbaum FR, Aljitawi OS, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood 2015;126:1033–40.

2. Luznik L, O’Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641–50.

3. Al Malki MM, Tsai N-C, Palmer J, Mokhtari S, Cao T, Ali H, et al. A Phase II trial of post-transplant cyclophosphamide as graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26:S188 3, Supplement.